Registry update — unassessed
Clinical Translation of Senolytic Therapy With Fisetin to Improve Vascular Function in Older Adults
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 25, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- The abstract presents only trial design and objectives, with no outcome data, so no efficacy claims can be assessed.
- Sample size, treatment duration, dosing, and follow-up period are not specified, limiting ability to interpret the trial's power and scope.
- Without reported results, safety, tolerability, and adherence cannot be evaluated.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Older adults
- Primary outcome
- Vascular endothelial function and aortic stiffness
- Effect size
- —
- Significance
- Not reported
- Journal
- University of Colorado, Boulder
- Published
- Sep 25, 2026
Sources
Primary source
- University of Colorado, Boulder ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 2. This is not a claim of full-text review.
This is a pilot clinical trial to test the efficacy of intermittent treatment with the flavonoid compound fisetin for improving vascular endothelial function and reducing aortic stiffness in older adults.
This trial will also determine the potential mechanisms by which fisetin may improve vascular function, including by decreasing mitochondrial oxidative stress, cellular senescence and senescence-associated secretory phenotype (SASP) factors in circulation.
Lastly, safety, tolerability and adherence of fisetin treatment will be assessed.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.